Zeng Zhijun, Chen Mengjie, Liu Yimin, Zhou Yun, Liu Hongning, Wang Shaohua, Ji Yanhua
Jiangxi University of Chinese Medicine, Nanchang, China.
Research Center for Differentiation and Development of TCM Basic Theory, Jiangxi Province Key Laboratory of TCM Etiopathogenesis, Jiangxi University of Chinese Medicine, Nanchang, China.
J Gastroenterol Hepatol. 2025 Jan;40(1):19-32. doi: 10.1111/jgh.16747. Epub 2024 Oct 13.
Insulin resistance (IR) is a pathogenic factor in numerous metabolic diseases. The gut microbiota plays a crucial role in maintaining the function of the intestinal barrier and overall human health, thereby influencing IR. Dysbiosis of the gut microbiota can contribute to the development of IR. Therefore, it is essential to maintain a balanced and diverse gut microbiota for optimal health. Akkermansia muciniphila, a widely present microorganism in the human intestine, has been shown to regulate gastrointestinal mucosal barrier integrity, reduce endotoxin penetration, decrease systemic inflammation levels, and improve insulin sensitivity. Reduced abundance of A. muciniphila is associated with an increased risk of IR and other metabolic diseases, highlighting its correlation with IR. Understanding the role and regulatory mechanism of A. muciniphila is crucial for comprehending IR pathogenesis and developing novel strategies for preventing and treating related metabolic disorders. Individual variations may exist in both the gut microbiota composition and its impact on IR among different individuals. Further investigation into individual differences between A. muciniphila and IR will facilitate advancements in personalized medicine by promoting tailored interventions based on the gut microbiota composition, which is a potential future direction that would optimize insulin sensitivity while preventing metabolic disease occurrence. In this review, we describe the physiological characteristics of A. muciniphila, emphasize its roles in underlying mechanisms contributing to IR pathology, and summarize how alterations in its abundance affect IR development, thereby providing valuable insights for further research on A. muciniphila, as well as new drug development targeting diabetes.
胰岛素抵抗(IR)是众多代谢性疾病的致病因素。肠道微生物群在维持肠道屏障功能和整体人类健康方面发挥着关键作用,进而影响胰岛素抵抗。肠道微生物群的失调会促使胰岛素抵抗的发展。因此,维持肠道微生物群的平衡和多样性对于保持最佳健康状态至关重要。嗜黏蛋白阿克曼氏菌是人类肠道中广泛存在的一种微生物,已被证明可调节胃肠道黏膜屏障的完整性,减少内毒素渗透,降低全身炎症水平,并改善胰岛素敏感性。嗜黏蛋白阿克曼氏菌丰度的降低与胰岛素抵抗及其他代谢性疾病风险的增加相关,凸显了其与胰岛素抵抗的关联。了解嗜黏蛋白阿克曼氏菌的作用和调控机制对于理解胰岛素抵抗的发病机制以及制定预防和治疗相关代谢紊乱的新策略至关重要。不同个体之间的肠道微生物群组成及其对胰岛素抵抗的影响可能存在个体差异。进一步研究嗜黏蛋白阿克曼氏菌与胰岛素抵抗之间的个体差异,将通过推动基于肠道微生物群组成的个性化干预措施来促进个性化医学的发展,这是一个潜在的未来方向,既能优化胰岛素敏感性,又能预防代谢疾病的发生。在本综述中,我们描述了嗜黏蛋白阿克曼氏菌的生理特征,强调了其在导致胰岛素抵抗病理的潜在机制中的作用,并总结了其丰度变化如何影响胰岛素抵抗的发展,从而为进一步研究嗜黏蛋白阿克曼氏菌以及开发针对糖尿病的新药提供有价值的见解。